Kazakhstan and Tether Explore Tenge Stablecoin and RWA Tokenization 
China Shuts 670 Banks as Bitcoin Eyes Financial Risks 
Intel Reaffirms Role in Elon Musk’s Terafab Chip Project 
OKX Raises Fresh Funding at $25 Billion Valuation 
GSR Commits $100M to Hare Onchain Credit Vaults 
German Industrial Orders Plunge 10.6% in August 
Securitize, LG CNS Partner on South Korea Tokenization 
Trump Plans Diesel Tax Relief as Fuel Prices Hit Record Highs 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Indian Stocks Fall as RBI Hikes Rates to 5.50% 
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal 
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 
3 clinical-grade skincare creams you really shouldn’t buy online 
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
RBI Raises Repo Rate to 5.50% in Hawkish Shift on Inflation Risks 
Asian Currencies Steady as Dollar Holds Near 18-Month High 
Add as a preferred source on Google
Kubota Pharmaceutical will sell specially designed glasses dubbed Kubota Glass, which it claims are able to reverse the effects of myopia.
The glasses shine tiny lights at the retina to simulate short-distance blurring, forcing the user to look further ahead and in doing so taking the pressure of the axial deformation of eyeballs.
Long-term testing is still required to gauge how effective Kubota Glass is at this in detail, but studies so far suggest that they are at least effective at curbing the progression of myopia.
Kubota Glass has been approved as a medical device in Taiwan and the USA.
Kubota Pharmaceutical charges 770,000 yen for a pair of Kubota Glass while offering a 100-percent satisfaction guarantee.
According to 2009 research conducted by Japan's Ministry of Education, Culture, Sports, Science, and Technology, around 25% of first-graders had less than perfect eyesight, with the percentage rising to 50% among sixth-graders.
